Samsung Bioepis Presents Three-year Follow-up Results of SB5 (biosimilar, adalimumab) for Psoriasis at EADV 2022
Shots:
- The company reported the 3yr. follow up results from the study evaluating adalimumab biosimilars in 1059 patients with psoriasis
- The results showed the safety and effectiveness of SB5 in patients with psoriasis who have started or transitioned from reference adalimumab, persistence rate after 3yr. therapy was 72.1%, treatments discontinued in 25.1%, and mean (± SD) SB5 treatment duration was 19.3mos. ± 9.1, cumulative persistence rate of 1/2/3yr. (79.7%/73.5%/72.1%), respectively
- The therapy has been the EU in Aug 2017, under the brand name Imraldi as a biosimilar to Humira. Biogen gets an exclusive marketing right to Imraldi along with Benepali and Flixabi in the EU
Ref: Globenewswire | Image: Samsung Bioepis
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
